Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Magnevist (SH L 451A)
Magnevist · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | ACTIVE_COMPARATOR | - |
| Arm 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Magnevist (SH L 451A) | DRUG | Magnevist at a dose of 0.1 mmol/kg |
| Magnevist (Gadopentetate dimeglumine, BAY86-4882) | DRUG | One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period1:Magnevist 0.1 mmol/kg body weightperiod 2: Magnevist 0.2 mmol/kg body weight |
Inclusion Criteria: * Patients who are confirmed to have 1-5 metastatic brain tumor by the latest contrast-enhanced cerebral CT or contrast-enhanced cerebral MRI, and the lesion(s) have not been treated by surgery or by stereotactic radiosurgery. Exclusion Criteria: * Patients who are scheduled t...
Magnevist is a gadolinium-based contrast agent used to enhance magnetic resonance imaging. In clinical development it has been studied in patients with brain neoplasms, including brain metastasis, and in patients with documented myocardial infarction, where it is used to help depict delayed enhancement of heart tissue on MRI.
Magnevist is developed and manufactured by Bayer AG, which trades over the counter in the United States under the ticker BAYRY. Bayer is the sponsor responsible for the clinical studies of the agent in brain neoplasms and myocardial infarction.
Magnevist has been studied in Phase 3 clinical development, with one completed Phase 3 trial in patients with brain metastasis. A separate completed Phase 2 study evaluated the agent in patients with documented myocardial infarction. No active trials of Magnevist are currently listed.
Magnevist has been evaluated in two completed studies. NCT00681551 was a Phase 3 intra-individual dose comparison study in patients with brain metastasis conducted in Japan. NCT00310544 was a Phase 2 study of delayed enhancement depiction in patients with documented myocardial infarction run in the United States and Argentina.
Yes. Magnevist is the brand name for gadopentetate dimeglumine, and the compound has also been referenced by the development codes BAY86-4882 and SH L 451A. Searches for any of these names refer to the same gadolinium-based MRI contrast agent from Bayer.
The Magnevist clinical program listed here enrolled a total of 73 patients across its completed studies. The Phase 3 brain metastasis trial, NCT00681551, enrolled 45 patients, and the Phase 2 myocardial infarction study, NCT00310544, enrolled 73 patients.